World's Best Scientists 2026 revealed!
Michael Pfreundschuh

Michael Pfreundschuh

D-Index & Metrics

Medicine

D-Index
113
Citations
56323
World Ranking
4882
National Ranking
268

Overview

Michael Pfreundschuh was affiliated with Saarland University in Germany. Their research primarily focused on medicine, with a substantial number of publications addressing pathology and forensic medicine, oncology, immunology, genetics, and radiology, nuclear medicine, and imaging.

The scientist's main research topics included lymphoma diagnosis and treatment, chronic lymphocytic leukemia research, CNS lymphoma diagnosis and treatment, immune cell function and interaction, medical imaging techniques and applications, CAR-T cell therapy research, and viral-associated cancers and disorders.

Their recent published papers included the following:

  • Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial (2020, Leukemia)
  • Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma (2020, Nature Communications)
  • FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials (2021, European Journal of Nuclear Medicine and Molecular Imaging)
  • Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma (2020, Haematologica)
  • VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma (2020, European Journal Of Haematology)

Frequent co-authors included Lorenz Thurner, Dominic Kaddu-Mulindwa, Moritz Bewarder, Gerhard Held, and Marita Ziepert.

The scientist published regularly in venues such as Haematologica, eJHaem, Leukemia, Nature Communications, and the European Journal of Nuclear Medicine and Molecular Imaging.

Best Publications

  • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

    Michael Pfreundschuh;Lorenz Trümper;Anders Österborg;Ruth Pettengell

  • Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

    Bjoern Chapuy;Chip Stewart;Andrew J Dunford;Jaegil Kim

  • A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

    Yao-Tseng Chen;Matthew J. Scanlan;Ugur Sahin;Özlem Türeci

  • Human neoplasms elicit multiple specific immune responses in the autologous host.

    Ugur Sahin;Ozlem Tureci;Holger Schmitt;Bjorn Cochlovius

  • Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

    Michael Pfreundschuh;Joerg Schubert;Marita Ziepert;Rudolf Schmits

  • Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

    Volker Diehl;Jeremy Franklin;Michael Pfreundschuh;Bernd Lathan

  • A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

    Eva Hoster;Martin Dreyling;Wolfram Klapper;Christian Gisselbrecht

  • Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari

  • CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

    Michael Pfreundschuh;Evelyn Kuhnt;Lorenz Trümper;Anders Österborg

  • Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

    Michael Pfreundschuh;Lorenz Trümper;Marita Kloess;Rudolf Schmits

  • Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    H Tilly;M Gomes da Silva;U Vitolo;A Jack

  • Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

    Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova

  • Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era

    Marita Ziepert;Dirk Hasenclever;Evelyn Kuhnt;Bertram Glass

  • Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

    Norbert Schmitz;Lorenz Trümper;Marita Ziepert;Maike Nickelsen

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

    Michael Pfreundschuh;Lorenz Trümper;Marita Kloess;Rudolf Schmits

  • MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

    Heike Horn;Marita Ziepert;Claudia Becher;Thomas F. E. Barth

  • Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

    Andreas Engert;Volker Diehl;Jeremy Franklin;Andreas Lohri

  • Treatment of Older Patients with Mantle-Cell Lymphoma

    H. C. Kluin-Nelemans;Eva Hoster;Olivier Hermine;J. Walewski

  • NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity

    Leszek Wojnowski;Bettina Kulle;Markus Schirmer;Gregor Schlüter

Frequent Co-Authors

Norbert Schmitz
Norbert Schmitz University of Münster
Lorenz Trümper
Lorenz Trümper University of Göttingen
Markus Loeffler
Markus Loeffler Leipzig University
Lothar Kanz
Lothar Kanz University of Tübingen
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Rüdiger Hehlmann
Rüdiger Hehlmann Heidelberg University
Stefan W. Krause
Stefan W. Krause University of Erlangen-Nuremberg
Michael Kneba
Michael Kneba Kiel University
Hermann Einsele
Hermann Einsele University of Würzburg
Ugur Sahin
Ugur Sahin Johannes Gutenberg University of Mainz

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in healthcare doesn't just mean attending a traditional medical school. There are many flexible online degree options for those interested in the medical field, especially in nursing. For instance, if you're aiming to advance your nursing credentials without incurring high costs, consider the cheapest online dnp programs as a path to leadership and advanced practice roles.

Registered Nurses looking to boost their qualifications can explore the cheapest rn to bsn pathways, which offer accessible and affordable advancement opportunities. For individuals with a non-nursing bachelor's degree who wish to switch careers, direct entry nurse practitioner programs for non-nurses online provide a fast track into advanced nursing roles without starting from scratch.

Additionally, for those seeking the most accessible nursing education, different online adn programs can help you enter the workforce quickly as a registered nurse. With so many options, online degrees can help you find the right fit for your goals in medicine and healthcare.

Best Scientists Citing Michael Pfreundschuh

Recently Published Articles